IONIS Pharmaceuticals, Inc. — Q1 2015 Form 10-Q Summary
Business context and reporting period
Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals) filed its unaudited Form 10-Q for the three months ended March 31, 2015. The company develops RNA-targeted antisense medicines and primarily funds operations through collaborative research, licensing and milestone agreements. In 2015, it began reporting two segments: Isis Core and newly formed, wholly owned Akcea Therapeutics, which focuses on lipid-related drugs.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $62.6 million | $28.2 million | +122% |
| R&D collaboration revenue | $61.9 million | $19.6 million | +216% |
| Licensing and royalty revenue | $0.7 million | $8.6 million | -92% |
| Operating expenses | $71.9 million | $57.8 million | +24% |
| Loss from operations | $(9.3) million | $(29.7) million | Improved |
| Net loss | $(16.7) million | $(31.3) million | Improved |
| Net loss per share | $(0.14) | $(0.27) | Improved |
| Net cash used in operations | $(42.8) million | $(32.3) million | Higher use |
Calculated operating margin was approximately negative 14.9%, compared with negative 105.4% in Q1 2014. Net loss margin was approximately negative 26.7%, compared with negative 111.1%. The filing does not report gross profit or gross margin because the company presents operating expenses rather than cost of revenue.
- Cash and cash equivalents were $148.3 million at March 31, 2015, compared with $143.0 million at December 31, 2014.
- Short-term investments were $546.7 million, resulting in cash, cash equivalents and short-term investments of approximately $695.1 million.
- Working capital was $735.1 million, compared with $721.3 million at year-end 2014.
- Stockholders’ equity was $275.9 million; accumulated deficit was approximately $1.0 billion.
- Total debt and other obligations were $642.7 million. Convertible debt included $500.0 million of 1% notes due 2021 and $61.2 million of 2¾% notes due 2019.
- Contractual obligations totaled $763.1 million, including principal, interest, facility rent, leases and other obligations.
- Stock-based compensation was $13.3 million, compared with $7.1 million in Q1 2014, and was a significant component of operating expense growth.
Material changes versus the prior comparable period
- Revenue increased primarily because of $46 million in milestone payments, including $31 million from Biogen and $15 million from GSK. Approximately 75% of Q1 2015 revenue came from milestone payments.
- Biogen represented 63% of revenue, and GSK represented 26%; the concentration of revenue among partners increased from the prior year.
- Research, development and patent expenses increased to $64.4 million from $53.4 million, reflecting advancement of Phase 3 programs for ISIS-TTR Rx, ISIS-SMN Rx and ISIS-APOCIII Rx.
- General and administrative expense increased to $7.5 million from $4.4 million, partly because of Akcea-related activities and higher stock compensation.
- Interest expense increased to $9.0 million from $4.9 million, primarily due to the 1% convertible notes issued in November 2014 and related non-cash debt-discount amortization.
- Operating cash use increased to $42.8 million, driven in part by a $23.0 million increase in contracts receivable and reductions in accrued liabilities and deferred contract revenue.
- The Regulus investment increased in value to $93.4 million from $81.9 million at December 31, 2014. Unrealized investment gains contributed $7.4 million to other comprehensive income.
- Akcea incurred $7.1 million of operating loss and had no revenue during the quarter.
Guidance, outlook, commentary and unusual items
- Management expected Phase 3 data in 2016 or 2017 for ISIS-APOCIII Rx, ISIS-SMN Rx and ISIS-TTR Rx, potentially supporting regulatory filings.
- The company reported 38 drugs in development and identified ISIS-APOCIII Rx, ISIS-SMN Rx and ISIS-TTR Rx as significant near-term opportunities. KYNAMRO was marketed in the United States for homozygous familial hypercholesterolemia, with Genzyme responsible for commercialization.
- Management projected $85 million to $95 million of new revenue in 2015 from the Bayer HealthCare license agreement. The filing also described expected payments from Bayer, including a $100 million upfront payment and a $55 million milestone, subject to Hart-Scott-Rodino clearance.
- Subsequent events described in the filing included the Bayer HealthCare license, a Janssen collaboration, an Alnylam cross-license and additional partner payments. These events occurred after March 31, 2015 and should not be treated as Q1 recognized revenue unless specifically stated.
- The company stated that it intended to use existing cash, cash equivalents and short-term investments to finance operations, but may seek equity, debt, refinancing or credit facilities depending on business and market conditions.
- Key risks include continued losses, dependence on collaboration and milestone revenue, partner termination or reduced funding, clinical and regulatory failure, commercialization and reimbursement risk, KYNAMRO acceptance and safety limitations, manufacturing capacity, intellectual-property litigation and potential future financing needs.
- The Santaris litigation was settled in March 2015. Gilead litigation concerning patents jointly owned with Merck remained outstanding; Merck was responsible for litigation costs under the applicable agreement.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2015 and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether projected 2015 Bayer revenue and related payments were ultimately received and recognized, including the status of regulatory clearance.
- The sustainability and timing of milestone-driven revenue, particularly the concentration in Biogen and GSK.
- Progress, enrollment, safety and efficacy results for the Phase 3 programs for ISIS-APOCIII Rx, ISIS-SMN Rx and ISIS-TTR Rx.
- Akcea’s funding requirements, operating losses and progress toward development or commercialization of its lipid franchise.
- Liquidity after recurring operating cash burn, debt service and the company’s $763.1 million of disclosed contractual obligations.
- Potential dilution or cash settlement associated with convertible notes, which were convertible into approximately 11.2 million shares in aggregate based on the disclosed conversion terms.
- Regulatory, safety, reimbursement and commercial performance risks affecting KYNAMRO and other pipeline products.
- Changes in the fair value of the Regulus investment and the effect of future market volatility on comprehensive income and equity.